Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Stock pick for 2024: Take advantage of this 'generational opportunity' to buy Conduit

Conduit Holdings (CRE) is the parent company of Conduit Re, a Bermuda-based pure-play reinsurance company which launched in December 2020 when the holding company listed on the London Stock Exchange.
The firm writes reinsurance policies across property, casualty and specialty lines, always making sure its risk is neutral across different sectors and geographies based on an in-depth view of the underlying assets and the specific risk factors.
Having been established in 2020, the firm has no baggage in terms of ‘legacy’ policies which might come back to bite it, which is a big differentiating factor for investors who are used to buying financial stocks and insurers in particular.
It is this lack of ‘skeletons in the cupboard’, together with the expertise of the management team and the current ‘hard market’ in insurance which makes Conduit Re such an exciting prospect.
According to chief executive Trevor Carvey, it typically takes 18 months for written premiums to flow through to the bottom line, which means the firm is now seeing the benefit of business it took on mid-way through 2022.
To give some impression of how fast the company is growing, it wrote more than $900 million worth of premiums in the first nine months of this year, an increase of 56% on this time last year, and since inception it has written $2 billion with what is called ‘unearned premium’ of $676 million which is yet to flow through to profits.
This means in less than three years the firm has almost hit its five-year target already, Carvey tells Shares.
This is no flash in the pan, however, as the insurance market is going through one of its once-in-a-generation phases of sharply rising rates.
‘Trevor and his team have created a scalable business model and a platform that is delivering strong organic sustainable growth and we have an ample capital base that will enable us to continue to do so,’ says chairman Neil Eckert.
‘We expect the duration of the current hard cycle to be extended due to structural changes in the industry, continued inflationary pressures and adverse development on the industry’s legacy casualty business.’
Analysts at Berenberg agree, calling this a ‘generational opportunity’ across the London reinsurance market, with significant ‘upside risks’ to earnings forecasts in the absence of any major natural catastrophes. Conduit Re has avoided the worst impact of these as most of the risk so far has been carried by the insurers themselves.
Important information:
These articles are provided by Shares magazine which is published by AJ Bell Media, a part of AJ Bell. Shares is not written by AJ Bell.
Shares is provided for your general information and use and is not a personal recommendation to invest. It is not intended to be relied upon by you in making or not making any investment decisions. The investments referred to in these articles will not be suitable for all investors. If in doubt please seek appropriate independent financial advice.
Investors acting on the information in these articles do so at their own risk and AJ Bell Media and its staff do not accept liability for losses suffered by investors as a result of their investment decisions.
Issue contents
Case study
Feature
- Return from our 2023 share picks is more than four times that of the UK market
- The best and worst emerging markets in 2023
- Can electricals leader Currys deliver some turnaround spark?
- Discover the stocks the professionals changed their minds on in 2023
- Emerging markets: China property fixes and dollar weakness
Great Ideas
- 10 stocks for 2024: our best ideas for the year ahead
- Stock pick for 2024: Adobe is one of the best ways to play AI
- Stock pick for 2024: Buy Smith & Nephew for continued recovery and re-rating potential
- Stock pick for 2024: Buy Puretech Health for lower risk access to an exciting drug portfolio
- Stock pick for 2024: MongoDB is one of the hottest software plays on AI
- Stock pick for 2024: B&M's growth ambitions and value focus make it a compelling story
- Stock pick for 2024: Hunting is attractively priced and evidence of transformation is a clear catalyst
- Stock pick for 2024: The market has not spotted RELX for the AI winner it is
- Stock pick for 2024: Just Group is so cheap and has big growth drivers behind it
- Stock pick for 2024: Hollywood Bowl is a strikingly resilient operator trading at the wrong price
- Stock pick for 2024: Take advantage of this 'generational opportunity' to buy Conduit
Investment Trusts
News
- How TSMC could set the New Year tone for tech
- Markets higher despite mixed rates messaging and what to expect from retailers
- Discover the most unloved and most-shorted UK stocks
- Costco climbs to all-time high as members clamour for cheap essentials
- A big acquisition and a slowdown in its largest market have unnerved investors in Rentokil
- UK housebuilders Taylor Wimpey and Persimmon have moved-up strongly